BioSpaceOriginal article
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
Phase 2Mixedanti-TL1A antibodyNeutral
AI Analysis
Summary
Merck's anti-TL1A antibody from its $10.8B Prometheus acquisition showed positive Phase 2b results in a skin condition but failed in a lung disease indication. Results were disclosed alongside the company's second-quarter earnings.
Clinical Trial Data
Phase
2b
Outcome Details
positive results in skin condition, failed in certain type of lung disease
Importance:6/10
Sentiment:
0.15
Phase 2b resultsacquisitionmixed trial outcomeearnings release
Related Companies
Read the original article
Published by BioSpace on August 4, 2026 3:23 PM